Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Zai Lab Limited (ZLAB)

26.48 +1.18 (+4.66%)
At close: September 2 at 4:00:00 PM EDT
26.00 -0.48 (-1.81%)
Pre-Market: 5:00:03 AM EDT
Trade Zai Lab on Coinbase
Chart Range Bar
Loading chart for ZLAB
  • Previous Close 25.30
  • Open 26.24
  • Bid 13.12 x 200
  • Ask 23.88 x 200
  • Day's Range 26.00 - 27.50
  • 52 Week Range 15.96 - 34.72
  • Volume 1,056,843
  • Avg. Volume 1,003,819
  • Market Cap (intraday) 2.973B
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) --
  • EPS (TTM) -1.78
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 33.14

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

www.zailaboratory.com

1,784

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

ZLAB
50.20%
HANG SENG INDEX (^HSI)
1.63%

1-Year Return

ZLAB
20.58%
HANG SENG INDEX (^HSI)
0.51%

3-Year Return

ZLAB
1.46%
HANG SENG INDEX (^HSI)
37.16%

5-Year Return

ZLAB
81.88%
HANG SENG INDEX (^HSI)
2.66%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 106.31M
Earnings -50.83M
Profit Margin -47.81%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-50M
0
50M
100M
-50.0%
-45.0%
-40.0%
-35.0%

Analyst Insights

View More

Analyst Price Targets

24.25
33.14 Average
26.48 Current
50.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/7/2026
Analyst Citigroup
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 44 -> 45

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    2.78B

  • Enterprise Value

    2.42B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.24

  • Price/Book (mrq)

    4.68

  • Enterprise Value/Revenue

    5.38

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -41.86%

  • Return on Assets (ttm)

    -14.75%

  • Return on Equity (ttm)

    -26.91%

  • Revenue (ttm)

    449.61M

  • Net Income Avi to Common (ttm)

    -188.21M

  • Diluted EPS (ttm)

    -1.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    617.52M

  • Total Debt/Equity (mrq)

    41.94%

  • Levered Free Cash Flow (ttm)

    -83.96M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

26.48 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 01/05/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 09/15/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 06/30/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 04/04/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: